Literature DB >> 17067994

Expression of ADAMTS-5/implantin in human decidual stromal cells: regulatory effects of cytokines.

H Zhu1, P C K Leung, C D MacCalman.   

Abstract

BACKGROUND: The restricted expression of ADAMTS-5 (A Disintegrin And Metalloproteinase with ThromboSpondin repeats-5) to the maternal-fetal interface in mice has led to this novel metalloproteinase being assigned the trivial name 'implantin'.
METHODS: As a first step in determining whether ADAMTS-5 also contributes to the implantation process in humans, we have examined the spatiotemporal expression of this ADAMTS subtype in the endometrium during the menstrual cycle and pregnancy by immunohistochemical analysis. A quantitative competitive PCR (QC-PCR) strategy and western blotting were subsequently used to determine whether interleukin (IL)-1beta and transforming growth factor (TGF)-beta1, two cytokines involved in the formation of the maternal-fetal interface, were capable of regulating ADAMTS-5 messenger RNA (mRNA) and protein levels in primary cultures of stromal cells isolated from first trimester decidual tissues.
RESULTS: ADAMTS-5 expression in the stroma of the human endometrium correlates with decidualization of this cellular compartment in vivo. IL-1beta was found to increase (P < 0.05) whereas TGF-beta1 decreased (P < 0.05) ADAMTS-5 mRNA and protein levels in decidual stromal cell cultures in a concentration- and time-dependent manner. These regulatory effects were attenuated by function-perturbing antibodies directed against either cytokine.
CONCLUSIONS: ADAMTS-5 expression is restricted to decidualized stromal cells of the human endometrium in vivo and is subject to regulation by cytokines in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17067994     DOI: 10.1093/humrep/del356

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Characterization of the transcriptome of chorioamniotic membranes at the site of rupture in spontaneous labor at term.

Authors:  Chia-Ling Nhan-Chang; Roberto Romero; Adi L Tarca; Pooja Mittal; Juan Pedro Kusanovic; Offer Erez; Shali Mazaki-Tovi; Tinnakorn Chaiworapongsa; John Hotra; Nandor Gabor Than; Jung-Sun Kim; Sonia S Hassan; Chong Jai Kim
Journal:  Am J Obstet Gynecol       Date:  2010-05       Impact factor: 8.661

2.  Expression profile of microRNAs and mRNAs in human placentas from pregnancies complicated by preeclampsia and preterm labor.

Authors:  Kathleen Mayor-Lynn; Tannaz Toloubeydokhti; Amelia C Cruz; Nasser Chegini
Journal:  Reprod Sci       Date:  2010-11-15       Impact factor: 3.060

Review 3.  A new biological marker candidate in female reproductive system diseases: Matrix metalloproteinase with thrombospondin motifs (ADAMTS).

Authors:  Kadir Demircan; İsmail Cömertoğlu; Sümeyya Akyol; Beyza Nur Yiğitoğlu; Esma Sarıkaya
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-12-01

4.  Expression of ADAMTS13 in Normal and Abnormal Placentae and Its Potential Role in Angiogenesis and Placenta Development.

Authors:  Juan Xiao; Yun Feng; Xueyin Li; Wei Li; Lei Fan; Jing Liu; Xue Zeng; Kaiyue Chen; Xi Chen; Xiaoshui Zhou; X Long Zheng; Suhua Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-27       Impact factor: 8.311

5.  The IL-1β/AP-1/miR-30a/ADAMTS-5 axis regulates cartilage matrix degradation in human osteoarthritis.

Authors:  Quanbo Ji; Xiaojie Xu; Qiang Zhang; Lei Kang; Yameng Xu; Ke Zhang; Ling Li; Yingchun Liang; Tian Hong; Qinong Ye; Yan Wang
Journal:  J Mol Med (Berl)       Date:  2016-04-11       Impact factor: 4.599

6.  Role of Versican and ADAMTS-1 in Polycystic Ovary Syndrome.

Authors:  Sibel Özler; Efser Öztaş; Aytekin Tokmak; Merve Ergin; Meryem Kuru Pekcan; Başak Gümüş Güler; Halil İbrahim Yakut; Nafiye Yılmaz
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-12-02

7.  Gonadal steroids regulate the expression of aggrecanases in human endometrial stromal cells in vitro.

Authors:  Jiadi Wen; Hua Zhu; Peter C K Leung
Journal:  J Cell Mol Med       Date:  2013-08-15       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.